Evaluating Current Practices in Shelf Life Estimation

被引:8
作者
Capen, Robert [1 ,2 ]
Christopher, David [1 ]
Forenzo, Patrick [3 ]
Huynh-Ba, Kim [4 ]
LeBlond, David
Liu, Oscar [5 ]
O'Neill, John [6 ]
Patterson, Nate [7 ]
Quinlan, Michelle [8 ]
Rajagopalan, Radhika [9 ]
Schwenke, James [10 ]
Stroup, Walter [11 ]
机构
[1] Merck, CMC Stat, West Point, PA 19486 USA
[2] Merck & Co Inc, WP 35-240,770 Sumneytown Pike, West Point, PA 19486 USA
[3] Novartis, Analyt Res & Dev, E Hanover, NJ USA
[4] Pharmalytik Consulting & Training Serv, Newark, DE USA
[5] Insys Therapeut, Res & Dev, Chandler, AZ USA
[6] Nagano Sci, Albany, NY USA
[7] Bayer US, Berkeley, CA USA
[8] Novartis Oncol, Clin Pharmacol Biostat, E Hanover, NJ USA
[9] US FDA, CDER, OPQ, OLDP, Silver Spring, MD USA
[10] Appl Res Consultants, New Milford, CT USA
[11] Univ Nebraska, Stat, Lincoln, NE USA
来源
AAPS PHARMSCITECH | 2018年 / 19卷 / 02期
关键词
stability; shelf life estimation; FDA; ICH Q1A/Q1E; managing risk;
D O I
10.1208/s12249-017-0880-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The current International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) methods for determining the supported shelf life of a drug product, described in ICH guidance documents Q1A and Q1E, are evaluated in this paper. To support this evaluation, an industry data set is used which is comprised of 26 individual stability batches of a common drug product where most batches are measured over a 24 month storage period. Using randomly sampled sets of 3 or 6 batches from the industry data set, the current ICH methods are assessed from three perspectives. First, the distributional properties of the supported shelf lives are summarized and compared to the distributional properties of the true shelf lives associated with the industry data set, assuming the industry data set represents a finite population of drug product batches for discussion purposes. Second, the results of the ICH "poolability" tests for model selection are summarized and the separate shelf life distributions from the possible alternative models are compared. Finally, the ICH methods are evaluated in terms of their ability to manage risk. Shelf life estimates that are too long result in an unacceptable percentage of nonconforming batches at expiry while those that are too short put the manufacturer at risk of possibly having to prematurely discard safe and efficacious drug product. Based on the analysis of the industry data set, the ICH-recommended approach did not produce supported shelf lives that effectively managed risk. Alternative approaches are required.
引用
收藏
页码:668 / 680
页数:13
相关论文
共 5 条
[1]  
[Anonymous], 2003, INT C HARM TECHN REQ
[2]   On the Shelf Life of Pharmaceutical Products [J].
Capen, Robert ;
Christopher, David ;
Forenzo, Patrick ;
Ireland, Charles ;
Liu, Oscar ;
Lyapustina, Svetlana ;
O'Neill, John ;
Patterson, Nate ;
Quinlan, Michelle ;
Sandell, Dennis ;
Schwenke, James ;
Stroup, Walter ;
Tougas, Terrence .
AAPS PHARMSCITECH, 2012, 13 (03) :911-918
[3]   A new approach to estimating shelf-life [J].
Kiermeier, A ;
Jarrett, RG ;
Verbyla, AP .
PHARMACEUTICAL STATISTICS, 2004, 3 (01) :3-11
[4]   ESTIMATING A SINGLE SHELF-LIFE FOR MULTIPLE BATCHES [J].
Kiermeier, Andreas ;
Verbyla, Arunas P. ;
Jarrett, Richard G. .
AUSTRALIAN & NEW ZEALAND JOURNAL OF STATISTICS, 2012, 54 (03) :343-358
[5]   Evaluating the Performance of the ICH Guidelines for Shelf Life Estimation [J].
Quinlan, Michelle ;
Stroup, Walter ;
Schwenke, James ;
Christopher, David .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2013, 23 (04) :881-896